The Gavathiotis laboratory investigates the structure and function of protein interactions to elucidate the molecular mechanisms that regulate cell death and survival signaling pathways and are deregulated in pathological processes such as cancer and cardiovascular disease. The overarching goal of our research is to translate mechanistic insights of protein interactions into novel pharmacologic strategies and develop therapeutics that can lead to cures.
Dr. Gavathiotis will give a talk on "Probing BAX-Mediated Cell Death in Cancer with Small Molecule BAX Activators" at Cell Death - Cold Spring Harbor Meeting.
Our lab is studying signaling pathways of pancreatic cancer and melanoma to identify potential drug targets and prevent tumor growth and spread. See more in Einstein Connection that highlights our work.
Dr. Evripidis Gavathiotis has been selected as the 2013 Sinsheimer Scholar Award recipient by the Alexandrine and Alexander L. Sinsheimer Foundation. The foundation provides "funding to individuals who demonstrate potential for making major contributions with respect to the prevention or cure of human disease."
Tom receives the "best poster award" in the Annual Chemical Biology Symposium organized by the New York Academy of Sciences!
The Kimmel Scholar Awards were created to advance the careers of gifted, young scientists involved in cancer research. Those selected are chosen for demonstrating the greatest promise and innovation in their work, must be in the early stages of their research career, and have not progressed far enough to have received major grants from the National Cancer Institute or other funding sources.
A new paper from Anguiano et al. in Nature Chemical Biology demonstrates a structure-based design of RARα antagonists that leads to compounds that can selectively upregulate chaperone-mediated autophagy (CMA), yielding the first chemically tractable target for regulating CMA in cells!
The Foundation funds innovative clinical or basic science research that will lead to novel therapeutic approaches that could replace, or be used in combination with existing effective therapies and improve the quality of life of patients with leukemia or lymphoma. Since its inception, Gabrielle's Angel Foundation has proudly distributed nearly $20 million in Medical Research Awards to more than 100 of the nation's leading junior investigators.